It has been a mixed year for Keros Therapeutics, Inc. insiders: $76,000 bought by one person and $181.2 million sold by 11, so more selling than buying overall.
Biggest single buyer: BIENAIME JEAN JACQUES, Director, with roughly $22,000.
Zooming out by quarter: 4 quarters in a row of net selling by insiders. Insiders bought in 4 of the last 7 full quarters. 132 investment managers listed KROS in their latest 13F filings (Q2 2026); more funds sold than bought.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 20, 2026 | Tanini Annita | Officer | Sell | 1,224 | $10.29 | $13K | SEC |
| Aug 20, 2026 | Lerner Lorena Raquel | Executive Officer | Sell | 3,568 | $10.29 | $37K | SEC |
| Aug 20, 2026 | Cho Esther | Executive Officer | Sell | 4,485 | $10.29 | $46K | SEC |
| Aug 20, 2026 | Newton Charles W. | Director | Sell | 551 | $10.30 | $6K | SEC |
| Aug 19, 2026 | BIENAIME JEAN JACQUES | Director | Buy | 1,000 | $10.27 | $10K | SEC |
| Jul 17, 2026 | BIENAIME JEAN JACQUES | Director | Buy | 1,000 | $10.61 | $11K | SEC |
| Jun 17, 2026 | BIENAIME JEAN JACQUES | Director | Buy | 1,000 | $10.19 | $10K | SEC |
| Jun 15, 2026 | Newton Charles W. | Director | Sell | 550 | $10.04 | $6K | SEC |
| Jun 8, 2026 | Farzan Nima | Director | Sell | 2,625 | $10.73 | $28K | SEC |
| Jun 8, 2026 | Knowles Julius | Director | Sell | 2,625 | $10.73 | $28K | SEC |
| Jun 5, 2026 | Seth Alpna | Director | Sell | 2,625 | $10.72 | $28K | SEC |
| May 19, 2026 | BIENAIME JEAN JACQUES | Director | Buy | 1,000 | $10.58 | $11K | SEC |
| Apr 17, 2026 | BIENAIME JEAN JACQUES | Director | Buy | 1,000 | $11.70 | $12K | SEC |
| Mar 11, 2026 | BIENAIME JEAN JACQUES | Director | Buy | 2,000 | $11.21 | $22K | SEC |
| Feb 20, 2026 | Cho Esther | Executive Officer | Sell | 4,745 | $16.35 | $78K | SEC |
In the last 12 months Keros Therapeutics, Inc. insiders made open-market purchases worth about $76,000 and sales worth about $181.2 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in KROS was filed on 2026-08-20.
132 investment managers reported holding KROS in SEC Form 13F filings for Q2 2026.
No congressional trades in KROS were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).